Home > Cardiology > ESC 2019 > Conference highlights > Beta-blockers reduce death in HF patients with moderate renal impairment

Beta-blockers reduce death in HF patients with moderate renal impairment

Conference
ESC 2019

Beta-blockers are an effective method to prevent mortality in patients with heart failure characterised by reduced ejection fraction (HFrEF) and sinus rhythm; this also applies to those individuals with moderate (eGFR 45-59 mL/min/1.73m2) or moderate-severe renal dysfunction (30-44 mL/min/1.73m2).

Renal insufficiency is a common feature in HF patients. The lack of evidence-based therapies in this population can be a real challenge. Kotecha and colleagues conducted an analysis using data from HFrEF patients (n=16,740) derived from 10 landmark, double-blind, placebo-controlled randomised trials to assess the role of beta-blockers in HF patients with renal impairment. Primary endpoint was all-cause mortality. Median age of the patients was 65 years; 23% were female and the median follow-up was 1.3 years. In general, it can be stated that renal dysfunction was independently associated with higher mortality. The cause of death was more often due to progressive ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on